Immunitybio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Immunitybio Inc (IBRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Immunitybio Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 166M vs 166,463M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+23.6% annualized vs trailing 12 months), vs accelerating (+2.2%) for its tracked peer group.
- Growth: Immunitybio Inc generated 93.9% revenue growth year over year in Q2 2026, vs 7.4% for its tracked competitors combined.
- Profitability: Its -449.6% net margin compares with -23.4% for the peer group.
- Scale: Immunitybio Inc ranks #16 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 1.0% of industry market cap.
- Peer revenue share: Immunitybio Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.24M compares with $1.08M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IBRX Sales vs. its Competitors, Q2 2026
Immunitybio Inc reported revenue growth of 93.91 % year on year in Q2 2026, above its competitors' combined revenue growth of 7.44 %.
With a net margin of -449.63 %, Immunitybio Inc reported lower profitability than its competitors (-23.38 %).
Immunitybio Inc generated 0.12 % of the combined sales of its peer group, up from 0.07 % a year earlier.
Immunitybio Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Immunitybio Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Immunitybio inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Immunitybio Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs 93.9% for Immunitybio Inc. Immunitybio Inc's share of combined industry revenue moved from 0.07% to 0.12%, a gain of 0.04 percentage points.
Immunitybio Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Immunitybio inc | No | Yes | Yes | No |
| Competitors combined (63) | ||||
| High-Confidence Competitors (14) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IBRX Stock Performance relative to its Competitors
IBRX Stock Performance relative to High-Confidence Competitors
IBRX Stock Performance relative to Similar-Size Competitors
IBRX Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Revolution Medicines Inc | 282.9% | Outperformed |
| 4 | Century Therapeutics inc | 282.9% | Outperformed |
| 5 | Cullinan Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Immunitybio Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Immunitybio inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Immunitybio inc | 8,946.60 | 165.79 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Gilead Sciences Inc | 189,197.03 | 30,457.00 |
| Bristol myers Squibb Company | 130,826.24 | 49,186.00 |
| Sanofi | 100,940.42 | 52,321.04 |
| SUBTOTAL | 1,406,744.39 | 308,372.11 |
Sign in to see all competitors of Immunitybio inc .
Sources: Immunitybio inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Immunitybio inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Immunitybio Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Urogen Pharma Ltd | Named by the company | 85% |
| Nkgen Biotech Inc | Named by the company | 85% |
| Atara Biotherapeutics, Inc. | Named by the company | 85% |
| Carina Biotech, Inc. | Named by the company | 85% |
| Medisix Therapeutics Pte Ltd. | Named by the company | 85% |
| Immutep Limited | Named by the company | 85% |
| Allogene Therapeutics, Inc. | Named by the company | 85% |
| Bluebird Bio, Inc. | Named by the company | 85% |
| JW Therapeutics Co., Ltd. | Named by the company | 85% |
| Precigen Corporation, Inc. | Named by the company | 85% |
| Carisma Therapeutics Inc | Named by the company | 85% |
| Beijing Immunochina Pharmaceuticals Co., Ltd. | Named by the company | 85% |
| Cellular Biomedicine Group, Inc. | Named by the company | 85% |
| Mesoblast Ltd. | Named by the company | 85% |
| Medicenna Therapeutics Corp. | Named by the company | 85% |
| Amgen, Inc. | Named by the company | 85% |
| Calibr/Scripps Research | Named by the company | 85% |
| Leucid Bio Ltd. | Named by the company | 85% |
| Igm Biosciences Inc | Named by the company | 85% |
| AbbVie Inc. | Named by the company | 85% |
| Bellicum Pharmaceuticals, Inc. | Named by the company | 85% |
| iCell Gene Therapeutics LLC | Named by the company | 85% |
| Mustang Bio, Inc. | Named by the company | 85% |
| Moderna Inc | Named by the company | 85% |
| Century Therapeutics inc | Named by the company | 85% |
| Celularity Inc | Named by the company | 85% |
| Sanofi | Named by the company | 85% |
| Gamida Cell Ltd | Named by the company | 85% |
| Nkarta Inc | Named by the company | 85% |
| Nektar Therapeutics | Named by the company | 85% |
| Takeda Pharmaceutical Company Limited | Named by the company | 85% |
| Inmune Bio Inc | Named by the company | 85% |
| Cg Oncology Inc | Named by the company | 85% |
| Protara Therapeutics Inc | Named by the company | 85% |
| Gritstone Bio Inc | Named by the company | 85% |
| Achilles Therapeutics Plc | Named by the company | 85% |
| AMRK | Named by the company | 85% |
| Novartis Ag | Named by the company | 85% |
| Fate Therapeutics Inc | Named by the company | 85% |
| Biontech Se | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Immunitybio Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Immunitybio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Immunitybio inc | Reportable 100.00 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Recursion Pharmaceuticals Inc | Reportable 100.00 % |
| Xencor Inc | Reportable 100.00 % |
| Novavax inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Immunitybio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Immunitybio inc | 8,947 | 239,931 | -1,436,207 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Gilead Sciences Inc | 189,197 | 1,791,588 | -190,588 |
| Bristol myers Squibb Company | 130,826 | 1,513,415 | 285,354 |
| Sanofi | 100,940 | 22,927,713 | 3,853,252 |
| PEERS TOTAL | 1,397,798 | 1,077,829 | 86,790 |
Immunitybio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Immunitybio inc | United States 98.99 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Krystal Biotech Inc | United States 75.19 % |
| Iovance Biotherapeutics inc | US 98.66 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Immunitybio Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Immunitybio Inc's industry classification, broader than the peer set above. Market cap in millions of $.Immunitybio Inc ranks #16 of 159 companies by market capitalization in its industry, holding 1.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 16 | Immunitybio inc | 8,773 | 1.01 % |
Market cap and industry share for the rest of Immunitybio Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Immunitybio Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 11 | Twist Bioscience Corporation | 11,478 | 587.59 % |
| 12 | Kymera Therapeutics Inc | 10,949 | 127.00 % |
| 13 | Repligen Corp | 10,757 | 56.09 % |
| 14 | Krystal Biotech Inc | 10,396 | 110.43 % |
| 15 | Qiagen N v | 1,234 | 12.3% |
| 16 | Immunitybio inc | 8,773 | 239.63 % |
| 17 | Vaxcyte Inc | 1,234 | 12.3% |
| 18 | Immunovant Inc | 1,234 | 12.3% |
| 19 | Scholar Rock Holding Corp | 1,234 | 12.3% |
| 20 | Cg Oncology Inc | 1,234 | 12.3% |
| 21 | Crispr Therapeutics Ag | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Immunitybio Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Immunitybio Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 99.34 % | 68.46 % (avg) | +30.9 pp |
| Operating Margin | -151.88 % | industry median | +53.1 pp |
| EBITDA Margin | -574.74 % | -0.94 % (avg) | -573.8 pp |
| Capital Intensity (Capex / Revenue) | 4.45 % | 6.74 % (avg) | -2.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Immunitybio Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | -11.0x | 5.1x | -16.1x |
| Return on Equity | 135.08 % | industry aggregate | 138.51 % |
| Return on Invested Capital | 111.47 % | -6.17 % (avg) | 117.64 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Immunitybio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 4.44 % | -8.51 % | 158.14 % | 500.00 % | -74.30 % | 159.17 % | 500.00 % | 500.00 % |
| Operating Margin | -209,338.30 % | -157,690.70 % | -82,545.95 % | -35,361.88 % | -146,374.17 % | -58,239.55 % | -2,334.23 % | -226.00 % |
| Return on Invested Capital | -27.76 % | -22.63 % | -32.80 % | 572.43 % | 90.45 % | 74.97 % | 173.38 % | 152.48 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Immunitybio Inc's Strategic Group Map
Every company in Immunitybio Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Immunitybio Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Immunitybio Inc's BCG Growth-Share Matrix
Relative market share (vs Immunitybio Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Immunitybio Inc falls in the Question Mark quadrant: relative market share of 0.04x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Immunitybio Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 4.45 % vs industry average 6.74 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Immunitybio Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Immunitybio Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Immunitybio Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Immunitybio Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Immunitybio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 53.1 points above the industry median.
- Return on equity 138.5 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+23.6% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.04x).
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (48.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Immunitybio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Immunitybio inc | 1.63 | 5.83 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Sanofi | 0.27 | 1.09 | 0.20 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Immunitybio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Immunitybio inc | Q2 2026 | +93.9 % | - |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Sanofi | Q4 2025 | +5.5 % | +39.7 % |
| PEERS TOTAL | +6.2 % | -52.9 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Immunitybio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Immunitybio inc | Q2 2026 | +119.1 % | +227.4 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Sanofi | Q4 2025 | -1.2 % | - |
Immunitybio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Immunitybio inc | - | - | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Gilead Sciences Inc | - | - | - |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Sanofi | 6.19% | 8.42% | 10.95% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Immunitybio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Immunitybio inc | - | 53.96 |
| Merck and Co Inc | 119.91 | 5.52 |
| Novartis Ag | 20.53 | 5.07 |
| Gilead Sciences Inc | - | 6.21 |
| Bristol myers Squibb Company | 14.06 | 2.66 |
| Sanofi | 11.43 | 1.93 |
| PEERS AVERAGE | 59.04 | 4.56 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.